Vaginal News and Research

RSS

Mesh surgery more effective for patients with pelvic organ prolapse

A Nordic multicentre study, headed by researchers from Karolinska Institutet in Sweden, shows that pelvic organ prolapse surgery using synthetic mesh can be more effective than traditional surgery.

12 May 2011

Starpharma inks licence agreement in Japan with Okamoto for VivaGel-coated condoms

Starpharma Holdings Limited today announced that it has signed a licence agreement with Okamoto Industries Inc in relation to the VivaGel(r)-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

10 May 2011

SRS Medical announces pelvic health program for women

SRS Medical today announced the formation of Restore Continence™, a women's pelvic health program based on the use of a comprehensive suite of medical devices for diagnosing and treating urinary incontinence.

3 May 2011

Simbionix to exhibit new training simulator for pelvic floor repair at ACOG

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.

3 May 2011

C-section deliveries have increased by 72%, episiotomy and forceps use have declined

Use of episiotomy, a surgical incision to widen the vaginal area during childbirth, fell by 60 percent between 1997 and 2008, according to the latest News and Numbers by the Agency for Healthcare Research and Quality.

29 Apr 2011

IL28B gene plays a key role in spontaneous HCV clearance in infants

New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.

28 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Fibulin-5 protein can help prevent pelvic organ prolapse development in women

Pelvic organ prolapse is a disabling condition that affects almost 50% of women over the age of 50. It occurs when the muscles and ligaments supporting a woman's pelvic organs weaken such that the pelvic organs slip out of place, often protruding into the vagina.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Gen-Probe receives FDA marketing clearance for APTIMA Trichomonas vaginalis assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

Cervical cancer vaccine target falls short: Report

Data from the Australian federal government shows that the target to immunize 80 per cent of 12-year-old girls against cervical cancer is not being met because many of them are failing to have all three doses of the vaccine. This potentially undermines the effectiveness of the $436 million program started in 2007.

19 Apr 2011

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

Probiotic may reduce rate of recurrent urinary tract infections in women

Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.

16 Apr 2011

Varian Medical Systems launches new brachytherapy applicator

Varian Medical Systems is introducing a new brachytherapy applicator for treating endometrial cancer patients after a hysterectomy. The Capri applicator, aimed at increasing patient comfort and allowing clinicians to better sculpt the radiotherapy dose, is being exhibited this week at the annual American Brachytherapy Society meeting in San Diego.

15 Apr 2011

NEJM: Perspectives from Aaron, Reinhardt, Iglehart, Annas, Chambers and others

This week's New England Journal of Medicine features perspectives from prominent authors on Medicare and Medicaid. NEJM granted KHN permission to excerpt substantial portions of these columns.

8 Apr 2011

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced the publication of Phase III PROCHIEVE® (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound in Obstetrics & Gynecology.

7 Apr 2011

Progesterone gel can reduce preterm birth in women with short cervix

A groundbreaking clinical study of a new method for preventing premature birth in millions of women each year, published in the medical journal Ultrasound in Obstetrics & Gynecology, shows that the rate of early preterm delivery in women can be reduced by 45 percent - simply by treating pregnant women at risk with a low-cost gel of natural progesterone during the midtrimester of pregnancy until term.

7 Apr 2011

Progesterone benefits women with short cervix, finds NIH study

A National Institutes of Health study has found that progesterone, a naturally occurring hormone, reduced the rate of preterm birth before the 33rd week of pregnancy by 45 percent among one category of at risk women.

7 Apr 2011

Vaginal News and Research

Mesh surgery more effective for patients with pelvic organ prolapse

Starpharma inks licence agreement in Japan with Okamoto for VivaGel-coated condoms

SRS Medical announces pelvic health program for women

Simbionix to exhibit new training simulator for pelvic floor repair at ACOG

C-section deliveries have increased by 72%, episiotomy and forceps use have declined

IL28B gene plays a key role in spontaneous HCV clearance in infants

Researchers develop protein-based inhibitor that can treat HPV

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Fibulin-5 protein can help prevent pelvic organ prolapse development in women

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Gen-Probe receives FDA marketing clearance for APTIMA Trichomonas vaginalis assay

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Cervical cancer vaccine target falls short: Report

African AIDS drug trial stopped prematurely

Probiotic may reduce rate of recurrent urinary tract infections in women

Varian Medical Systems launches new brachytherapy applicator

NEJM: Perspectives from Aaron, Reinhardt, Iglehart, Annas, Chambers and others

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Progesterone gel can reduce preterm birth in women with short cervix

Progesterone benefits women with short cervix, finds NIH study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News